Medindia LOGIN REGISTER
Medindia

Treat Aggressive Gum Infections With New Antibiotic-Delivery System

by Dr. Jayashree Gopinath on Apr 22 2023 11:17 PM
Listen to this article
0:00/0:00

Developing a liposome-based drug delivery system provides an alternative method of delivering antibiotics to treat aggressive periodontitis (gum infection).

 Treat Aggressive Gum Infections With New Antibiotic-Delivery System
Developing a nonsurgical drug delivery system that will enable the controlled delivery of antibiotics that helps to treat aggressive periodontitis in adolescents, shows recent research from the National Institutes of Health (NIH).
Aggressive periodontitis is a severe type of gum infection that destroys ligaments and bones, leading to tooth loss in otherwise healthy individuals. Traditional treatment typically involves deep cleaning and antibiotics.

The way these infections are typically treated is by scaling and planing, which essentially means scraping off the bacteria and then prescribing oral antibiotics. This tends to work, but sometimes the bacteria come back, and then you must start the course of antibiotics all over again. The more frequently you take antibiotics, the greater the chances the bacteria will become resistant to them.

Antibiotic resistance is indeed a growing problem. According to the Centers for Disease Control and Prevention, more than 2.8 million antimicrobial-resistant infections occur every year in the U.S., and more than 35,000 people die as a result.

Alternative Method of Delivering Antibiotics to Treat Aggressive Periodontitis

In previous work, researchers have shown that antibiotics can be encapsulated in liposomes—tiny, round vesicles that contain one or more membranes and can be used as a delivery mechanism. They have also shown that the toxin released by the periodontitis-causing bacteria, called leukotoxin, triggers the release of antibiotics.

Leukotoxin fights the body’s immune response by binding with cholesterol in the membrane of white blood cells, disrupting the membrane and killing the cells. So they are creating a liposome that has cholesterol.

As most of the toxin will bind to the liposome instead of the host cells. When the toxin binds to the liposome, it should cause a release of the antibiotics, killing the disease-causing bacteria.

This new research will support the cell culture work performed at the lab to determine if the approach can protect the host cells from the toxin while simultaneously killing the bacterial cells. They will do this using a "co-culture" model, in which human immune cells and bacterial cells are grown together.

Advertisement
They also like to continue showing the advantages of using controlled delivery strategies for antibiotics. Since this toxin they are working with is closely related to those that cause diseases like whooping cough and cholera and E. coli infections, this approach could be useful against a range of bacteria.

Looking at different delivery strategies for antibiotics represents a new direction. This is the first externally funded project to do this work, and it validates the idea that this approach has a lot of potential to solve problems with both disease and antibiotic resistance.

Advertisement


Source-Eurekalert


Advertisement